Thursday, August 28, 2025 12:08:58 PM
I too have scratched my head over the Advent deal. It does seem like a gift from Linda Powers to NWBO.
I agree with others who have posted that the deal vastly increases the number of employees in the company (historically NWBO has had 10-15 employees and Advent last I read has 80). Also, it will likely represent the first major step in a changing of the guard at NWBO with an infusion of younger talent who will lead the company forward on the manufacturing side. I do think that in the coming weeks we'll see announcements of major share/option/warrant awards to the Advent people.
I'm not sophisticated enough to understand the full logic for keeping Advent separate from NWBO but clearly Ms. Powers has proven the naysayers wrong about her motivations. In addition, I think it's quite possible this transaction will be looked upon as the benchmark moment when Ms. Powers turned the tables on the shorts. They likely wouldn't have anticipated such an "altruistic" move which in one fell swoop removes the major objection institutions and professional investors had to considering NWBO. Now, when they look at the company, they'll see only an extremely favorable risk/reward equation. Today's movement especially indicates to me that we're finally getting the traditional share price increase high quality medical advances usually get in the months leading up to a major regulatory decision. I think we're going to get to $.50 - $1.00 over the coming weeks and all eyes will turn to the MHRA for the announcement of their rulemaking on virtual controls.
I agree with others who have posted that the deal vastly increases the number of employees in the company (historically NWBO has had 10-15 employees and Advent last I read has 80). Also, it will likely represent the first major step in a changing of the guard at NWBO with an infusion of younger talent who will lead the company forward on the manufacturing side. I do think that in the coming weeks we'll see announcements of major share/option/warrant awards to the Advent people.
I'm not sophisticated enough to understand the full logic for keeping Advent separate from NWBO but clearly Ms. Powers has proven the naysayers wrong about her motivations. In addition, I think it's quite possible this transaction will be looked upon as the benchmark moment when Ms. Powers turned the tables on the shorts. They likely wouldn't have anticipated such an "altruistic" move which in one fell swoop removes the major objection institutions and professional investors had to considering NWBO. Now, when they look at the company, they'll see only an extremely favorable risk/reward equation. Today's movement especially indicates to me that we're finally getting the traditional share price increase high quality medical advances usually get in the months leading up to a major regulatory decision. I think we're going to get to $.50 - $1.00 over the coming weeks and all eyes will turn to the MHRA for the announcement of their rulemaking on virtual controls.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
